MedMira Completes First Shipment for China Government Tender 100,000 Rapid HIV Tests Dispatched to Kickstart High-Volume Global Marketing Strategy HALIFAX, March 30 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in rapid flow- through diagnostic technology, announced today that it has shipped the initial order of 100,000 units of the MiraWell(R) Rapid HIV Test to the People's Republic of China. This shipment is the beginning of an annual standing order to fulfill the Jilin provincial government public tender announced earlier this month. MedMira continues to be the only Canadian company approved by the China State Food and Drug Administration (SFDA) to import its rapid HIV test into the country. "National, provincial and local governments in China are entering into an active prevention phase in controlling HIV transmission where rapid, point-of-care HIV testing is the only means for effective combat," said Hermes Chan, President and Chief Operating Officer of MedMira. "With our rank as the number 1 rapid HIV test in overall performance, and an accuracy rating as equivalent to the conventional ELISA method in the recent China National CDC report, we are confident that our MiraWell(R) Rapid HIV test will continue to be the test of choice by all levels of government in controlling and preventing HIV infection in China." Chan continued, "Our global marketing strategy has achieved numerous successes in China, and our MiraWell(R) Rapid HIV test has become a well-recognized brand name by Chinese medical institutions for its highest quality and performance. We will continue to focus on our sales expansion and product development to meet the high demand in the country." About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in P.R. China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Investor Relations: Dr. James Smith, (902) 450-1588 or e-mail:

Copyright